Orexin antagonist

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

Retrieved on: 
Thursday, July 1, 2021
Branches of biology, Biology, G protein-coupled receptors, Orexin antagonist, Eisai, Orexin receptor, Insomnia, Orexin, Hong Kong Airlines, Sleep

TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Key Points: 
  • TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • Eisai received approval for DAYVIGO in Hong Kong on February 28, 2021, and this launch is the first for DAYVIGO in Asia outside of Japan.
  • (10)
    The anti-insomnia drug market in Hong Kong as of 2020 valued at approximately 8.4 million USD, comprising nearly 9% of the insomnia drug market in Asia (Hong Kong, India, Indonesia, Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand).
  • Sleep.

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Retrieved on: 
Wednesday, June 9, 2021
Chemical compounds, Psychoactive drugs, Branches of biology, Hypnotics, GABAA receptor positive allosteric modulators, Pyridines, Orexin antagonist, G protein-coupled receptors, Acetamides, Lemborexant, Orexin receptor, Zolpidem

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)

Retrieved on: 
Tuesday, August 25, 2020
Sleep disorders, Chemical compounds, Sleep, Branches of biology, Lemborexant, Insomnia, Irregular sleep–wake rhythm, Orexin, Orexin antagonist

Lemborexant acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythms.

Key Points: 
  • Lemborexant acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythms.
  • Lemborexant was approved in the U.S. for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, and was approved in Japan for the treatment of insomnia.
  • The clinical development of lemborexant in patients with Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with mild-to-moderate Alzheimer's dementia is ongoing.
  • (3),(4) In particular, older adults tend to have a higher prevalence rate with many experiencing insomnia symptoms for months to years.

Eisai to Present Latest Insomnia Research, Including Data on New Treatment DAYVIGO™ (lemborexant) CIV, at the SLEEP 2020 Virtual Conference

Retrieved on: 
Monday, August 24, 2020
Chemical compounds, Psychoactive drugs, Organic compounds, Hypnotics, RTT, GABAA receptor positive allosteric modulators, Nonbenzodiazepines, Sleep disorders, Insomnia, Orexin antagonist, Lemborexant, Zolpidem

Additional research to be presented will explore sleep onset and sleep maintenance responder profiles over 12 months of treatment with DAYVIGO, efficacy and safety of DAYVIGO in females of perimenopausal age with insomnia disorder, and impact of DAYVIGO treatment on fatigue severity.

Key Points: 
  • Additional research to be presented will explore sleep onset and sleep maintenance responder profiles over 12 months of treatment with DAYVIGO, efficacy and safety of DAYVIGO in females of perimenopausal age with insomnia disorder, and impact of DAYVIGO treatment on fatigue severity.
  • In addition, interim results from a multi-center pilot study evaluating the next-dose transition from zolpidem to DAYVIGO for the treatment of insomnia will be presented.
  • DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • CNS depressant effects may persist in some patients up to several days after discontinuing DAYVIGO.

Eisai Announces U.S. Availability of DAYVIGO® (lemborexant) CIV, a New Treatment Option for Adults With Insomnia

Retrieved on: 
Monday, June 1, 2020
Chemical compounds, Sleep, Organic compounds, Hypnotics, RTT, Psychiatric diagnosis, Sleep disorders, Lemborexant, Pyrimidines, Insomnia, Orexin antagonist, Orexin

"DAYVIGO may be an appropriate treatment option for some of these patients."

Key Points: 
  • "DAYVIGO may be an appropriate treatment option for some of these patients."
  • "DAYVIGO is the first FDA-approved insomnia medication with safety data over a 12-month treatment period and with sleep onset and sleep maintenance efficacy data over a six-month treatment period in a pivotal clinical study.
  • Eisai remains committed to discovering and developing innovative solutions to unmet medical needs that benefit patients and their families."
  • DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Orexin Receptor Type 2, Pipeline Review, H2 2019 - Inexia Ltd, Takeda Pharmaceutical & Idorsia Pharmaceutical Ltd - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 21, 2020
Health, Pharmaceutical, G protein-coupled receptors, Branches of biology, Cell biology, Hypocretin (orexin) receptor 2, Orexin receptor, Hypocretin (orexin) receptor 1, Orexin, TCS-OX2-29, Orexin antagonist

The "Orexin Receptor Type 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Orexin Receptor Type 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene.
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 8 molecules.
  • The latest report Orexin Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

U.S. FDA Approves Eisai's DAYVIGO™ (lemborexant) for the Treatment of Insomnia in Adult Patients

Retrieved on: 
Monday, December 23, 2019
Psychoactive drugs, Chemical compounds, Hypnotics, Branches of biology, Organofluorides, G protein-coupled receptors, Cyclopropanes, Lemborexant, Pyrimidines, Orexin antagonist, Orexin receptor, Orexin

Patients were randomized to placebo (n=325), DAYVIGO 5 mg (n=323), or DAYVIGO 10 mg (n=323) once nightly.

Key Points: 
  • Patients were randomized to placebo (n=325), DAYVIGO 5 mg (n=323), or DAYVIGO 10 mg (n=323) once nightly.
  • Patients were randomized to placebo (n=208), DAYVIGO 5 mg (n=266) or 10 mg (n=269), or active comparator (n=263) once nightly.
  • DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • Patients with Compromised Respiratory Function:
    The effect of DAYVIGO on respiratory function should be considered for patients with compromised respiratory function.